You are here

Neulasta

If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

Motley Fool

Coherus Biosciences

Flag link:

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

Endpoints

Flag link:

Under copycat attack, Amgen punches back with its own biosimilars

Under copycat attack, Amgen punches back with its own biosimilars

Fierce Pharma

Flag link:

A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering

A Key Novartis Drug Could Be Delayed — Why This Stock Is Cheering

Investors Business Daily

Coherus Biosciences

Flag link:

Coherus' Neulasta biosimilar surprises with strong early uptake

Coherus' Neulasta biosimilar surprises with strong early uptake

Biopharma Dive

Coherus Biosciences

Flag link:

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Biopharma Dive

Flag link:

Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Endpoints

Spectrum Pharmaceuticals

Flag link:

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Reuters

Coherus Biosciences

Flag link:

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

Endpoints

Flag link:

Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts

Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts

Biopharma Dive

Flag link:

Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?

Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?

Fierce Pharma

Flag link:

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval

Fierce Pharma

Flag link:

Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate

Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate

CP Wire

Coherus Biosciences

Flag link:

Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate

Coherus Biosciences

Flag link:

What to Expect From Amgen, Inc. in 2018

What to Expect From Amgen, Inc. in 2018

Motley Fool

Flag link:

Will 2018 Be Amgen Inc.'s Best Year Yet?

Will 2018 Be Amgen Inc.'s Best Year Yet?

Motley Fool

Flag link:

The 2018 biosimilar litigation landscape: A primer

The 2018 biosimilar litigation landscape: A primer

BioPharma Dive

Flag link:

Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster

Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster

Fierce Pharma

Flag link:

Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

Yahoo/Zacks.com

Flag link:

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Fierce Pharma

Flag link:

Pages